Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.
Approximately 25-30% of lung cancer patients lack mutations targeted by current therapies, necessitating novel approaches. New targets, including MTAP deletions, SMARC4, and p53 mutations, show ...
The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results